FibroGen posts Q3 revenue of $1.1 million with net loss of $13.1 million

Reuters11-11

FibroGen posts Q3 revenue of $1.1 million with net loss of $13.1 million

FibroGen Inc. reported total revenue from continuing operations of $1.1 million for the third quarter of 2025, up from $0.1 million in the same period of 2024. The company recorded a net loss from continuing operations of $13.1 million, or $3.25 per basic and diluted share, compared to a net loss of $48.3 million, or $12.01 per basic and diluted share, one year ago. As of September 30, 2025, FibroGen reported cash, cash equivalents, accounts receivable, and investments totaling $121.1 million, with expectations that these resources will fund operating plans into 2028. During the quarter, FibroGen completed the sale of its China operations to AstraZeneca for approximately $220 million and initiated a Phase 2 monotherapy trial of FG-3246 and its companion diagnostic FG-3180, with an interim analysis expected in the second half of 2026. The company also remains on track to submit a Phase 3 protocol for roxadustat in LR-MDS in the fourth quarter of 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. FibroGen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9572632-en) on November 10, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2582074978?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-11 05:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582074978","market":"nz","top_or_hot":-1,"title":"FibroGen posts Q3 revenue of $1.1 million with net loss of $13.1 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      FibroGen posts Q3 revenue of $1.1 million with net loss of $13.1 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        FibroGen Inc. reported total revenue from continuing operations of $1.1 million for the third quarter of 2025, up from $0.1 million in the same period of 2024. The company recorded a net loss from continuing operations of $13.1 million, or $3.25 per basic and diluted share, compared to a net loss of $48.3 million, or $12.01 per basic and diluted share, one year ago. As of September 30, 2025, FibroGen reported cash, cash equivalents, accounts receivable, and investments totaling $121.1 million, with expectations that these resources will fund operating plans into 2028. During the quarter, FibroGen completed the sale of its China operations to AstraZeneca for approximately $220 million and initiated a Phase 2 monotherapy trial of FG-3246 and its companion diagnostic FG-3180, with an interim analysis expected in the second half of 2026. The company also remains on track to submit a Phase 3 protocol for roxadustat in LR-MDS in the fourth quarter of 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. FibroGen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9572632-en) on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FibroGen posts Q3 revenue of $1.1 million with net loss of $13.1 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFibroGen posts Q3 revenue of $1.1 million with net loss of $13.1 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-11 05:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      FibroGen posts Q3 revenue of $1.1 million with net loss of $13.1 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        FibroGen Inc. reported total revenue from continuing operations of $1.1 million for the third quarter of 2025, up from $0.1 million in the same period of 2024. The company recorded a net loss from continuing operations of $13.1 million, or $3.25 per basic and diluted share, compared to a net loss of $48.3 million, or $12.01 per basic and diluted share, one year ago. As of September 30, 2025, FibroGen reported cash, cash equivalents, accounts receivable, and investments totaling $121.1 million, with expectations that these resources will fund operating plans into 2028. During the quarter, FibroGen completed the sale of its China operations to AstraZeneca for approximately $220 million and initiated a Phase 2 monotherapy trial of FG-3246 and its companion diagnostic FG-3180, with an interim analysis expected in the second half of 2026. The company also remains on track to submit a Phase 3 protocol for roxadustat in LR-MDS in the fourth quarter of 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. FibroGen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9572632-en) on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL1zlJMR:1","article_id":"2582074978","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582074978","pubTimestamp":1762808552,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"FibroGen Inc. reported total revenue from continuing operations of $1.1 million for the third quarter of 2025, up from $0.1 million in the same period of 2024. The company recorded a net loss from continuing operations of $13.1 million, or $3.25 per basic and diluted share, compared to a net loss of $48.3 million, or $12.01 per basic and diluted share, one year ago. As of September 30, 2025, FibroGen reported cash, cash equivalents, accounts receivable, and investments totaling $121.1 million, with expectations that these resources will fund operating plans into 2028. During the quarter, FibroGen completed the sale of its China operations to AstraZeneca for approximately $220 million and initiated a Phase 2 monotherapy trial of FG-3246 and its companion diagnostic FG-3180, with an interim analysis expected in the second half of 2026. The company also remains on track to submit a Phase 3 protocol for roxadustat in LR-MDS in the fourth quarter of 2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","FGEN":"FibroGen, Inc","BK4505":"高瓴资本持仓"},"translate_title":"FibroGen公布第三季度营收110万美元，净亏损1310万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FGEN":0.9},"content_text":"FibroGen posts Q3 revenue of $1.1 million with net loss of $13.1 million\n    \n\n        FibroGen Inc. reported total revenue from continuing operations of $1.1 million for the third quarter of 2025, up from $0.1 million in the same period of 2024. The company recorded a net loss from continuing operations of $13.1 million, or $3.25 per basic and diluted share, compared to a net loss of $48.3 million, or $12.01 per basic and diluted share, one year ago. As of September 30, 2025, FibroGen reported cash, cash equivalents, accounts receivable, and investments totaling $121.1 million, with expectations that these resources will fund operating plans into 2028. During the quarter, FibroGen completed the sale of its China operations to AstraZeneca for approximately $220 million and initiated a Phase 2 monotherapy trial of FG-3246 and its companion diagnostic FG-3180, with an interim analysis expected in the second half of 2026. The company also remains on track to submit a Phase 3 protocol for roxadustat in LR-MDS in the fourth quarter of 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. FibroGen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9572632-en) on November 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582074978","isCrawlerRequest":true}